Literature DB >> 20024526

[Guideline compliance in the treatment of schizophrenic patients. Introduction of a computer-assisted treatment pathway].

F Godemann1, K Blittersdorf, M Poschenrieder, H Klimitz, I Hauth, H Gutzmann.   

Abstract

BACKGROUND: The goal of S3 Guidelines for the Treatment of Schizophrenia was to improve the care of patients with schizophrenic psychoses. However, the publication of guidelines alone does not ensure their consistent implementation. The use of treatment pathways represents one possible approach to help implement the complex treatment recommendations contained in the S3 Guidelines. The first computer-assisted treatment pathway for patients with schizophrenic psychoses was successfully incorporated into the everyday routine of psychiatric hospitals. The aim of the present study was to systematically analyse the impact of this measure on guideline compliance.
MATERIALS AND METHODS: Based on the S3 Guidelines for the Treatment of Schizophrenia developed by the German Association of Psychiatry, Psychotherapy and Neurology (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde; DGPPN), diagnostic and treatment procedures were defined by a multiprofessional working group with members from five different hospitals and subsequently incorporated into an existing hospital information system. In one of the five hospitals, the impact of this measure was analysed in a pilot study in a systematic manner. In the year 2007, approximately 100 patients in each of two wards in the hospital received in a parallel group design either standard care or care based on a computer-assisted treatment pathway. Based on their place of residence, patients were assigned to the two units consecutively. Both groups were analysed to determine the extent to which the care they received conformed to treatment guidelines. Data available from the years 2004 and 2005 served as a historical comparison to the present results.
RESULTS: The differences in guideline compliance between the two wards were heterogeneous and, in certain respects, counterintuitive. As expected, the treatment pathway group showed an increased number of laboratory tests, more frequent drug screening at hospital admission and more appropriate dosing of neuroleptics. However, the rate of participation in psychoeducational interventions was disappointing. A conspicuous finding was the negative relationship between initial disease severity and compliance with guidelines on psychopharmacological treatment. In contrast, the historical comparison revealed that guideline compliance had increased slightly in both the treatment pathway and standard treatment groups.
CONCLUSION: Developing computer-assisted treatment pathways based on S3 Guidelines and incorporating them into existing hospital information systems is feasible and well accepted by users. The initial effects on guideline compliance are mostly positive, but not strongly so. Moreover, there was a reduction in duration of hospital stay. Disease-related factors such as disease severity appear to compromise guideline compliance.

Entities:  

Mesh:

Year:  2010        PMID: 20024526     DOI: 10.1007/s00115-009-2895-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  14 in total

1.  Do clinical pathways really improve clinical performance in mental health settings?

Authors:  Brett Emmerson; Aaron Frost; Lisa Fawcett; Emma Ballantyne; Warren Ward; Stan Catts
Journal:  Australas Psychiatry       Date:  2006-12       Impact factor: 1.369

Review 2.  [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making].

Authors:  H-J Möller; W Maier
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

3.  Fidelity outcomes in the National Implementing Evidence-Based Practices Project.

Authors:  Gregory J McHugo; Robert E Drake; Rob Whitley; Gary R Bond; Kikuko Campbell; Charles A Rapp; Howard H Goldman; Wilma J Lutz; Molly T Finnerty
Journal:  Psychiatr Serv       Date:  2007-10       Impact factor: 3.084

4.  Outcome evaluation needed to support evidence-based practice! Preface.

Authors:  Ulf Malm; Jonas Eberhard
Journal:  Acta Psychiatr Scand Suppl       Date:  2007

5.  Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.

Authors:  Barbara Dickey; Sharon-Lise T Normand; Sue Eisen; Richard Hermann; Paul Cleary; Dharma Cortés; Norma Ware
Journal:  Med Care       Date:  2006-09       Impact factor: 2.983

6.  [Guidelines based on decision support software. Quality management in neurological outpatient schizophrenia treatment].

Authors:  B Janssen; R Menke; F Pourhassan; D Gessner-Ozokyay; R Peters; W Gaebel
Journal:  Nervenarzt       Date:  2006-05       Impact factor: 1.214

7.  Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?

Authors:  F Godemann; M Linden; W Gaebel; W Köpke; P Müller; F Müller-Spahn; J Tegeler; A Pietzcker
Journal:  Eur Psychiatry       Date:  2003-03       Impact factor: 5.361

8.  Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice.

Authors:  Joyce C West; Joshua E Wilk; Mark Olfson; Donald S Rae; Steve Marcus; William E Narrow; Harold A Pincus; Darrel A Regier
Journal:  Psychiatr Serv       Date:  2005-03       Impact factor: 3.084

Review 9.  Defining and measuring clinical effectiveness in the treatment of schizophrenia.

Authors:  Henry A Nasrallah; Steven D Targum; Rajiv Tandon; Jeffrey S McCombs; Ruth Ross
Journal:  Psychiatr Serv       Date:  2005-03       Impact factor: 3.084

10.  [Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison].

Authors:  B Janssen; S Weinmann; M Berger; M Härter; T Held; M Leipert; H J Luderer; M Schwarz; T Steinert; W Gaebel
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

View more
  5 in total

Review 1.  [Treatment pathways in the care of patients with schizophrenia and depression].

Authors:  H J Salize; E Voß; A Werner; P Falkai; I Hauth
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  [Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].

Authors:  G Juckel; K Stahl; C Norra
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

3.  In reply.

Authors:  Bruno Steinacher
Journal:  Dtsch Arztebl Int       Date:  2013-03       Impact factor: 5.594

4.  Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders : Results from a pilot feasibility trial.

Authors:  Irina Franke; Sarah Thier; Anita Riecher-Rössler
Journal:  Neuropsychiatr       Date:  2016-11-07

5.  The effects of a clinical care pathway for schizophrenia: a before and after study in 114 patients.

Authors:  Bruno Steinacher; Lieselotte Mausolff; Burkhard Gusy
Journal:  Dtsch Arztebl Int       Date:  2012-11-16       Impact factor: 5.594

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.